JP2015147774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015147774A5 JP2015147774A5 JP2015047791A JP2015047791A JP2015147774A5 JP 2015147774 A5 JP2015147774 A5 JP 2015147774A5 JP 2015047791 A JP2015047791 A JP 2015047791A JP 2015047791 A JP2015047791 A JP 2015047791A JP 2015147774 A5 JP2015147774 A5 JP 2015147774A5
- Authority
- JP
- Japan
- Prior art keywords
- androstan
- ethynyl
- oxime
- hydroxyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XPZHAZFQUFNMAU-HKQXQEGQSA-N n-[(5r,8r,9s,10s,13s,14s)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-ylidene]hydroxylamine Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=NO)[C@@H]4[C@@H]3CC[C@H]21 XPZHAZFQUFNMAU-HKQXQEGQSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86065806P | 2006-11-21 | 2006-11-21 | |
| US60/860,658 | 2006-11-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097486A Division JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015147774A JP2015147774A (ja) | 2015-08-20 |
| JP2015147774A5 true JP2015147774A5 (enExample) | 2016-03-10 |
Family
ID=39429970
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097487A Expired - Fee Related JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2015047791A Pending JP2015147774A (ja) | 2006-11-21 | 2015-03-11 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537124A Expired - Fee Related JP5386362B2 (ja) | 2006-11-21 | 2007-11-20 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097486A Active JP5918170B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097485A Pending JP2013173781A (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
| JP2013097487A Expired - Fee Related JP5657052B2 (ja) | 2006-11-21 | 2013-05-07 | Ｃｎｓ疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US8580983B2 (enExample) |
| EP (4) | EP2711371B1 (enExample) |
| JP (5) | JP5386362B2 (enExample) |
| AU (1) | AU2007322423C1 (enExample) |
| BR (2) | BR122013033954B8 (enExample) |
| CA (2) | CA2833976C (enExample) |
| DK (3) | DK2097437T3 (enExample) |
| ES (3) | ES2607852T3 (enExample) |
| HU (3) | HUE033037T2 (enExample) |
| IN (1) | IN2014DN02014A (enExample) |
| MX (1) | MX2009005335A (enExample) |
| PL (3) | PL2792681T3 (enExample) |
| PT (1) | PT2097437E (enExample) |
| RU (1) | RU2458065C2 (enExample) |
| SI (1) | SI2097437T1 (enExample) |
| WO (1) | WO2008063128A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607852T3 (es) * | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| EP2523666B8 (en) | 2010-01-14 | 2016-04-06 | Asarina Pharma AB | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| US20130203718A1 (en) * | 2010-05-07 | 2013-08-08 | Marie-Edith Rafestin-Oblin | Progesterone receptor antagonists and uses thereof |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| CN105189529B (zh) * | 2012-11-28 | 2017-09-05 | 国家医疗保健研究所 | 孕烯醇酮的3‑(4’‑取代的)‑苄基‑醚衍生物 |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| US20160339040A1 (en) | 2014-01-29 | 2016-11-24 | Umecrine Cognition Ab | Steroid compound for use in the treatment of hepatic encephalopathy |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10774108B2 (en) * | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| TWI748936B (zh) * | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DE102015120587A1 (de) | 2015-11-26 | 2017-06-01 | Brandenburgische Technische Universität Cottbus-Senftenberg | Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| US11111266B2 (en) | 2016-10-18 | 2021-09-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3579842A4 (en) | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS |
| BR112019015362A2 (pt) | 2017-02-10 | 2020-10-20 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico |
| CN111432805B (zh) | 2017-11-27 | 2023-02-17 | 梅克里内科尼蒂翁公司 | 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂 |
| AU2019249932A1 (en) | 2018-04-05 | 2020-10-08 | Asarina Pharma Aps | GABA-A antagonists for treating substance withdrawal disorders |
| EP3909967A4 (en) | 2019-01-08 | 2022-11-09 | Chengdu Kanghong Pharmaceutical Co., Ltd. | STEROID COMPOUND AND USE THEREOF AND METHOD OF MANUFACTURE THEREOF |
| CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
| EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| EP4430057A1 (en) | 2021-11-10 | 2024-09-18 | Umecrine AB | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4429669A1 (en) | 2021-11-10 | 2024-09-18 | Umecrine AB | Steroid as a modulator of gabaa receptor |
| WO2023083979A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4389129A1 (en) * | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1463755A (fr) * | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
| US3152121A (en) * | 1962-03-16 | 1964-10-06 | Upjohn Co | 20-ketals of 3-hydroxy-5 beta-pregnan-20-one |
| CH491889A (de) | 1966-10-22 | 1970-06-15 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von Steroiden |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5234603A (en) | 1991-06-04 | 1993-08-10 | Analytical Development Corporation | Methods employing a zirconium salt for use in wastewater treatment |
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| ATE195654T1 (de) * | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| DE69519945T2 (de) | 1994-11-23 | 2001-06-07 | Cocensys, Inc. | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
| KR19990022323A (ko) * | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| AU756001B2 (en) | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| WO1999052532A1 (en) * | 1998-04-14 | 1999-10-21 | Pharmadigm, Inc. | Method for reducing central nervous system impairment |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| CZ294278B6 (cs) * | 1999-11-25 | 2004-11-10 | Ústav organické chemie a biochemie AV ČR | Neuroaktivní steroidy a způsob jejich přípravy |
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| FR2831441B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
| EP1310258A1 (en) | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| CA2585359C (en) * | 2004-11-18 | 2013-01-08 | Umecrine Ab | Gaba-steroid antagonists and their use for the treatment of cns disorders |
| ES2607852T3 (es) | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| US20130203718A1 (en) | 2010-05-07 | 2013-08-08 | Marie-Edith Rafestin-Oblin | Progesterone receptor antagonists and uses thereof |
-
2007
- 2007-11-20 ES ES14154304.1T patent/ES2607852T3/es active Active
- 2007-11-20 HU HUE14154304A patent/HUE033037T2/hu unknown
- 2007-11-20 BR BR122013033954A patent/BR122013033954B8/pt not_active IP Right Cessation
- 2007-11-20 RU RU2009107537/04A patent/RU2458065C2/ru active
- 2007-11-20 SI SI200731681T patent/SI2097437T1/sl unknown
- 2007-11-20 PL PL14154304T patent/PL2792681T3/pl unknown
- 2007-11-20 HU HUE13198584A patent/HUE036410T2/hu unknown
- 2007-11-20 DK DK07835459.4T patent/DK2097437T3/en active
- 2007-11-20 EP EP13198584.8A patent/EP2711371B1/en not_active Not-in-force
- 2007-11-20 MX MX2009005335A patent/MX2009005335A/es active IP Right Grant
- 2007-11-20 PT PT78354594T patent/PT2097437E/pt unknown
- 2007-11-20 EP EP13198608.5A patent/EP2711372A1/en not_active Withdrawn
- 2007-11-20 PL PL07835459T patent/PL2097437T3/pl unknown
- 2007-11-20 IN IN2014DEN2014 patent/IN2014DN02014A/en unknown
- 2007-11-20 JP JP2009537124A patent/JP5386362B2/ja not_active Expired - Fee Related
- 2007-11-20 PL PL13198584T patent/PL2711371T3/pl unknown
- 2007-11-20 EP EP14154304.1A patent/EP2792681B1/en not_active Not-in-force
- 2007-11-20 WO PCT/SE2007/050876 patent/WO2008063128A1/en not_active Ceased
- 2007-11-20 DK DK14154304.1T patent/DK2792681T3/en active
- 2007-11-20 BR BRPI0718945A patent/BRPI0718945B8/pt active IP Right Grant
- 2007-11-20 ES ES07835459.4T patent/ES2543841T3/es active Active
- 2007-11-20 AU AU2007322423A patent/AU2007322423C1/en active Active
- 2007-11-20 HU HUE07835459A patent/HUE026961T2/en unknown
- 2007-11-20 CA CA2833976A patent/CA2833976C/en active Active
- 2007-11-20 ES ES13198584.8T patent/ES2662500T3/es active Active
- 2007-11-20 DK DK13198584.8T patent/DK2711371T3/en active
- 2007-11-20 US US11/943,555 patent/US8580983B2/en not_active Expired - Fee Related
- 2007-11-20 CA CA2664126A patent/CA2664126C/en active Active
- 2007-11-20 EP EP07835459.4A patent/EP2097437B1/en active Active
-
2012
- 2012-12-17 US US13/716,794 patent/US20130102578A1/en not_active Abandoned
- 2012-12-17 US US13/716,984 patent/US20130102579A1/en not_active Abandoned
-
2013
- 2013-03-07 US US13/788,006 patent/US20140011792A1/en not_active Abandoned
- 2013-03-07 US US13/788,074 patent/US20140011793A1/en not_active Abandoned
- 2013-03-07 US US13/787,924 patent/US8853190B2/en active Active
- 2013-03-22 US US13/848,782 patent/US9200028B2/en active Active
- 2013-05-07 JP JP2013097486A patent/JP5918170B2/ja active Active
- 2013-05-07 JP JP2013097485A patent/JP2013173781A/ja active Pending
- 2013-05-07 JP JP2013097487A patent/JP5657052B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-11 JP JP2015047791A patent/JP2015147774A/ja active Pending
- 2015-07-10 US US14/796,301 patent/US20150315231A1/en not_active Abandoned
- 2015-11-19 US US14/945,575 patent/US20160272670A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015147774A5 (enExample) | ||
| NL301279I2 (nl) | Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| JP2013173782A5 (enExample) | ||
| NL301224I2 (nl) | Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301342I2 (nl) | Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| JP2013173781A5 (enExample) | ||
| NL301260I2 (nl) | Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| JP2018012698A5 (enExample) | ||
| HUE053737T2 (hu) | Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik | |
| JP2016196495A5 (enExample) | ||
| JP2016028081A5 (enExample) | ||
| JP2016065085A5 (enExample) | ||
| EP3112364A4 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
| JP2017508572A5 (enExample) | ||
| FIC20250026I1 (fi) | Niraparibi tai sen farmaseuttisesti hyväksytty suola etenkin niraparibitosylaatti etenkin niraparibitosylaattimonohydraatti, valinnaisesti yhdessä abirateronin ja erityisesti abirateroniasetaatin kanssa. | |
| JP2017137500A5 (enExample) | ||
| ZA201804423B (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses | |
| JP2016540360A5 (ja) | 基板処理システム及び基板処理方法 | |
| IL248785B (en) | Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents | |
| PT3421038T (pt) | Compostos de naftiridina, combinações médicas e sua utilização | |
| HUE055468T2 (hu) | Új vegyület és gyógyszerészetileg elfogadható sója | |
| HUE052211T2 (hu) | TLR7 agonista maleát-só, annak C,D és E kristályos formái, és a maleátsó és a kristályos formák elõállítási eljárásai és alkalmazásai | |
| WO2015114308A8 (en) | Steroid compound for use in the treatment of hepatic encephalopathy | |
| JP2017197541A5 (enExample) | ||
| JP2017149782A5 (enExample) |